日报更新时间：04-17 11:30
周报更新时间：04-11 03:39
今开价：79.12
最高价：79.6
成交量：868641.0
昨收价：78.77
最低价：78.07
最新价：79.4
中文名称：拜玛林制药
英文名称：Biomarin Pharmaceutical
行业：医疗
简介：Biomarin Pharmaceutical Inc.位于特拉华州，研发生产创新生物技术药物，治疗严重的疾病和健康问题
电话：1-415-5066700
1997年，Christopher Starr Ph.D. 和 Grant W. Denison Jr. 以从Glyko Biomedical获得的150万美金创立了BioMarin，并于1999年IPO，种子投资公司包括MPM Bioventures、Grosvenor Fund 和 Florian Schönharting。拜玛林制药公司主要从事慢性基因疾病以酵素为基材的治疗药品的研发逾开发工作，BioMarin Pharmaceutical公司已推出的药品 BM101是针对黏多糖体病症(乡MPS-1)的儿童进行治疗的产品。后续并推出BM102，进行黏多糖体(MPS-VI)的治疗。另有多种利用碳水化合物分析法，开发它种酵素治疗产品。拜玛林制药公司商用阶段药物包括： Vimizim——酶替代疗法治疗MPS IV A（一种溶酶体贮积症）； Naglazyme——N-乙酰基-4-硫酸酯酶的重组形式，治疗VI型粘多糖体病症； Kuvan——6R-BH4的专有合成的口服剂型，用于治疗苯丙酮尿症患者（PKU，一种遗传代谢性疾病）； Aldurazyme—— 用于治疗I型粘多糖体病症（一种遗传性疾病）； Firdapse——3,4-二氨基吡啶，用于兰伯特肌无力综合征的治疗（一种自身免疫性疾病）。拜玛林制药公司临床阶段药物包括： Kyndrisa——一种exon-51 skipping化合物，用于治疗杜兴氏肌营养不良的（DMD）； Pegvaliase——酶替代疗法，用于治疗PKU； Reveglucosidase阿尔法——酶替代疗法治疗庞贝氏症； Vosoritide——肽疗法，用于治疗软骨发育不全症； BMN 044、BMN 045、BMN 053——用于DMD治疗； Cerliponase阿尔法——用于婴儿神经元蜡样脂褐质的治疗； BMN 270——一种用于治疗A型血友病的AAV VIII矢量、Factor VIII基因治疗药物； 此外，BioMarin Pharmaceutical还有临床前阶段产品，如：治疗遗传和代谢性疾病的α-N-乙酰氨基葡（alpha-N-acetyglucosaminidase）。拜玛林制药公司BioMarin Pharmaceutical(BMRN)收购历史： 2002年，拜玛林制药公司收购Glyko Biomedical； 2009年，BioMarin Pharmaceutical收购Huxley Pharmaceuticals, Inc.； 2010年，拜玛林制药公司收购LEAD Therapeutics, Inc.、ZyStor Therapeutics, Inc.； 2012年，BioMarin Pharmaceutical收购Zacharon Pharmaceuticals； 2014年，拜玛林制药公司以200万美金从Repligen(NASDAQ:RGEN)收购组蛋白去乙酰化酶抑制剂化学库； 2014年11月，BioMarin Pharmaceutical以8.4亿美金收购Prosensa(原NASDAQ:RNA)。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-07-08 | Anderson (Elizabeth M) | Director | Buy | 4490 | -- |
| 2019-06-16 | Lawlis (V Bryan) | Director | Sell | 3750 | 81.08 |
| 2019-06-16 | Lawlis (V Bryan) | Director | Buy | 3750 | 21.51 |
| 2019-06-10 | Meier (Richard A) | Director | Gift | 6000 | -- |
| 2019-06-04 | Ajer (Jeffrey Robert) | Officer | Buy | 14160 | -- |
| 2019-06-04 | Baffi (Robert A) | Officer | Buy | 14160 | -- |
| 2019-06-04 | Davis (George Eric) | General Counsel | Gift | 300 | -- |
| 2019-06-03 | Hombach (Robert J) | Director | Buy | 4430 | -- |
| 2019-06-03 | Lawlis (V Bryan) | Director | Buy | 4430 | -- |
| 2019-06-03 | Lewis (Alan J. Ph.D.) | Director | Buy | 4430 | -- |
| 2019-06-03 | Meier (Richard A) | Director | Buy | 4430 | -- |
| 2019-06-03 | Pyott (David E I) | Director | Buy | 4430 | -- |
| 2019-06-03 | Slamon (Dennis J) | Director | Buy | 4430 | -- |
| 2019-06-03 | Heron (Elaine J) | Director | Buy | 4430 | -- |
| 2019-06-03 | Grey (Michael G.) | Director | Buy | 4430 | -- |
| 2019-06-03 | Dere Willard H | Director | Buy | 4430 | -- |
| 2019-05-09 | Bienaime (Jean-Jacques) | Chief Executive Officer | Buy | 10000 | 14.39 |
| 2019-05-09 | Bienaime (Jean-Jacques) | Chief Executive Officer | Sell | 10000 | 82.52 |
| 2019-05-08 | Bienaime (Jean-Jacques) | Chief Executive Officer | Sell | 4000 | 81.97 |
| 2019-05-08 | Bienaime (Jean-Jacques) | Chief Executive Officer | Buy | 4000 | 14.39 |
| 2019-05-07 | Bienaime (Jean-Jacques) | Chief Executive Officer | Buy | 4000 | 14.39 |
| 2019-05-07 | Bienaime (Jean-Jacques) | Chief Executive Officer | Sell | 4000 | 82.16 |
| 2019-04-29 | Bienaime (Jean-Jacques) | Chief Executive Officer | Buy | 309 | 68.78 |
| 2019-04-29 | Ajer (Jeffrey Robert) | Officer | Buy | 309 | 68.78 |
| 2019-04-29 | Spiegelman (Daniel Keith) | Chief Financial Officer | Buy | 176 | 68.78 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| T. Rowe Price Associates, Inc. | 2481541 | 1.39% | 207251 | 9.11% | 2019-03-31 |
| Sands Capital Management, LLC | 5881446 | 3.28% | -226014 | -3.70% | 2019-03-31 |
| Baker Bros Advisors LP | 7589294 | 4.24% | -- | -- | 2019-03-31 |
| Jennison Associates LLC | 12412593 | 6.93% | 812133 | 7.00% | 2019-03-31 |
| BlackRock Inc | 12663369 | 7.07% | -915193 | -6.74% | 2019-03-31 |
| PRIMECAP Management Company | 14190873 | 7.92% | 5700 | 0.04% | 2019-03-31 |
| Vanguard Group Inc | 15709874 | 8.77% | 167970 | 1.08% | 2019-03-31 |
| Capital Research Global Investors | 17749061 | 9.91% | -555102 | -3.03% | 2019-03-31 |
| Capital Research and Management Company | 23917470 | 13.33% | 2837884 | 13.46% | 2019-07-31 |
| Viking Global Investors LP | 5128909 | 2.86% | 37272 | 0.73% | 2019-03-31 |
| ClearBridge Advisors, LLC | 5005318 | 2.80% | 499656 | 11.09% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 4981111 | 2.78% | 11444 | 0.23% | 2019-07-31 |
| Waddell & Reed Investment Management Co | 2523973 | 1.41% | -336902 | -11.78% | 2019-03-31 |
| Waddell & Reed Financial Inc | 2523973 | 1.41% | -336902 | -11.78% | 2019-03-31 |
| Legg Mason Partners Fund Advisor, LLC | 2534310 | 1.41% | 444733 | 21.28% | 2019-07-31 |
| Palo Alto Investors, LLC | 2641485 | 1.48% | 81752 | 3.19% | 2019-03-31 |
| Ameriprise Financial Inc | 2653174 | 1.48% | -8046 | -0.30% | 2019-03-31 |
| Harbor Capital Advisors Inc | 2893136 | 1.61% | -883415 | -23.39% | 2019-07-31 |
| BlackRock Fund Advisors | 4241109 | 2.36% | 14769 | 0.35% | 2019-07-31 |
| State Street Corporation | 4636152 | 2.59% | 738589 | 18.95% | 2019-03-31 |
| Amvescap Plc. | 3315049 | 1.85% | 17892 | 0.54% | 2018-12-31 |
| PGIM Investments LLC | 2887350 | 1.61% | -325195 | -10.12% | 2019-06-30 |
| Geode Capital Management, LLC | 3287014 | 1.84% | 1736026 | 111.93% | 2018-12-31 |
| Capital Research & Mgmt Co - Division 3 | 3412644 | 1.91% | 1308641 | 62.20% | 2018-12-31 |
| TIAA-CREF Investment Management LLC | 2638888 | 1.48% | 1574735 | 147.98% | 2018-09-30 |
| Goldman Sachs Group Inc | 2742244 | 1.54% | -484416 | -15.01% | 2018-06-30 |
| Fidelity Management & Research Company | 3701360 | 2.08% | -714159 | -16.17% | 2018-11-30 |
| BlackRock Institutional Trust Company NA | 4565488 | 2.56% | -121511 | -2.59% | 2018-06-30 |
| Temasek Holdings Ltd. | 3472712 | 1.95% | -- | -- | 2018-06-30 |
| State Street Corp | 3803137 | 2.14% | -220199 | -5.47% | 2018-06-30 |
| Fidelity Management and Research Company | 2051024 | 1.16% | -1894587 | -48.02% | 2018-06-30 |
| Goldman, Sachs & Co. | 1997247 | 1.13% | -337219 | -14.45% | 2018-06-30 |
| Citadel Advisors Llc | 1833405 | 1.03% | 457896 | 33.29% | 2018-06-30 |
| Capital World Investors | 1833103 | 1.03% | 158184 | 9.44% | 2018-06-30 |
| Invesco Advisers, Inc | 1673112 | 0.94% | -908767 | -35.20% | 2018-06-30 |
| venBio Select Advisor LLC | 1622770 | 0.91% | -88225 | -5.16% | 2018-06-30 |
| Prudential Investment Management Inc | 11968395 | 6.81% | 2571492 | 27.37% | 2017-12-31 |
| Franklin Advisers Inc | 1470212 | 0.84% | 83868 | 6.05% | 2017-12-31 |
| Balyasny Asset Management LLC | 1751391 | 1.00% | 689779 | 64.97% | 2017-12-31 |
| Manning & Napier Advisors, LLC | 2065710 | 1.18% | -52776 | -2.49% | 2017-09-30 |
| Invesco PowerShares Capital Mgmt LLC | 1374642 | 0.78% | -109332 | -7.37% | 2017-06-30 |
| OppenheimerFunds Inc | 1348373 | 0.77% | -239577 | -15.09% | 2017-09-30 |
| J.P. Morgan Investment Management Inc | 2945421 | 1.72% | 362380 | 14.03% | 2016-09-30 |
| Wells Capital Management Inc. | 1888612 | 1.10% | -243530 | -11.42% | 2016-09-30 |
| Fred Alger Management Inc | 1644829 | 0.96% | 209042 | 14.56% | 2016-09-30 |
| Columbia Mangmt Investment Advisers, LLC | 1479114 | 0.86% | 20003 | 1.37% | 2016-09-30 |
| The Vanguard Group | 8848001 | 3.00% | 1107504285 | 0.10% | 1999-11-30 |
| BlackRock, Inc. | 9237747 | 3.00% | 1156288792 | 0.10% | 1999-11-30 |
| FMR LLC | 13431666 | 3.00% | 1681241633 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| T. Rowe Price Health Sciences Fund | 1141988 | 0.64% | -176000 | -13.35% | 2019-06-30 |
| Vanguard Extended Market Index Fund | 2457210 | 1.37% | -8497 | -0.34% | 2019-06-30 |
| Harbor Capital Appreciation Fund | 2893136 | 1.61% | -883415 | -23.39% | 2019-06-30 |
| Vanguard PrimeCap Fund | 4138741 | 2.31% | -- | -- | 2019-03-31 |
| Vanguard Mid-Cap Index Fund | 4362161 | 2.43% | 84313 | 1.97% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 4909180 | 2.74% | 6869 | 0.14% | 2019-06-30 |
| Vanguard Capital Opportunity Fund | 5087160 | 2.83% | -10000 | -0.20% | 2019-03-31 |
| American Funds AMCAP Fund | 8939900 | 4.98% | -- | -- | 2019-06-30 |
| American Funds Growth Fund of Amer | 9647315 | 5.38% | 2405800 | 33.22% | 2019-06-30 |
| ClearBridge Large Cap Growth Fund | 1857322 | 1.03% | 389011 | 26.49% | 2019-06-30 |
| iShares Nasdaq Biotechnology ETF | 1767716 | 0.99% | 18395 | 1.05% | 2019-07-30 |
| PrimeCap Odyssey Growth Fund | 1735296 | 0.97% | -- | -- | 2019-06-30 |
| Vanguard Morgan | 1160222 | 0.65% | -137242 | -10.58% | 2019-03-31 |
| First Trust NYSE Arca Biotech Fund | 1165702 | 0.65% | -2809 | -0.24% | 2019-07-31 |
| CREF Growth Account | 1194128 | 0.67% | 243900 | 25.67% | 2019-06-30 |
| Vanguard Growth Index Fund | 1279574 | 0.71% | 49762 | 4.05% | 2019-06-30 |
| American Funds New World Fund | 1357279 | 0.76% | -- | -- | 2019-06-30 |
| American Funds American Balanced Fund | 1451000 | 0.81% | 141000 | 10.76% | 2019-06-30 |
| PrimeCap Odyssey Aggressive Growth Fund | 1482165 | 0.83% | 4000 | 0.27% | 2019-06-30 |
| Invesco QQQ Trust | 1608320 | 0.90% | 1421 | 0.09% | 2019-07-31 |
| Vanguard Mid-Cap Growth Index Fund | 1140148 | 0.64% | 51264 | 4.71% | 2019-06-30 |
| PGIM Jennison Health Sciences Fund | 1103318 | 0.62% | -- | -- | 2019-05-31 |
| Ivy Science and Technology Fund | 1021600 | 0.57% | -49600 | -4.63% | 2018-12-31 |
| VA CollegeAmerica AMCAP Fd | 10177000 | 5.71% | -168500 | -1.63% | 2018-12-31 |
| VA CollegeAmerica The Gr Fd of Amer | 8145515 | 4.57% | -420000 | -4.90% | 2018-12-31 |
| VA CollegeAmerica New Wld Fd | 1595179 | 0.89% | 104000 | 6.97% | 2018-12-31 |
| AZ InvestEd Ivy Science & Tech Fund | 1021600 | 0.57% | -49600 | -4.63% | 2018-12-31 |
| VA CollegeAmerica The New Economy Fd | 1543730 | 0.87% | 8600 | 0.56% | 2018-09-30 |
| American Funds New Economy Fund | 1543730 | 0.87% | 8600 | 0.56% | 2018-09-30 |
| Fidelity | 1100371 | 0.62% | -90000 | -7.56% | 2018-09-30 |
| PRIMECAP Odyssey Growth | 1726296 | 0.97% | 41980 | 2.49% | 2018-06-30 |
| AZ InvestEd Ivy Science & Tech E | 1071200 | 0.60% | -- | -- | 2018-06-30 |
| Vanguard Mid-Cap Growth ETF | 1073173 | 0.60% | 4664 | 0.44% | 2018-07-31 |
| VA CollegeAmerica New World 529F | 1242179 | 0.70% | 75000 | 6.43% | 2018-06-30 |
| VA CollegeAmerica Amcap 529F | 10345500 | 5.83% | -- | -- | 2018-06-30 |
| Vanguard Capital Opportunity Inv | 5092160 | 2.87% | 31480 | 0.62% | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 4439861 | 2.50% | 19892 | 0.45% | 2018-07-31 |
| Vanguard Mid Cap Index I | 4184831 | 2.36% | 23786 | 0.57% | 2018-07-31 |
| Vanguard PRIMECAP Inv | 4111290 | 2.32% | 305190 | 8.02% | 2018-06-30 |
| Harbor Capital Appreciation Instl | 3335218 | 1.88% | -27388 | -0.81% | 2018-06-30 |
| Vanguard Extended Market Idx Inv | 2343885 | 1.32% | 40505 | 1.76% | 2018-07-31 |
| iShares Nasdaq Biotechnology | 2004917 | 1.11% | -3816 | -0.19% | 2018-09-12 |
| VA CollegeAmerica Grth Fund of Amer 529F | 8201515 | 4.62% | 68000 | 0.84% | 2018-06-30 |
| Vanguard Growth Index Inv | 1243864 | 0.70% | -3480 | -0.28% | 2018-07-31 |
| T. Rowe Price Health Sciences | 1466067 | 0.83% | 235220 | 19.11% | 2018-06-30 |
| PRIMECAP Odyssey Aggressive Growth | 1486865 | 0.84% | 22860 | 1.56% | 2018-06-30 |
| Prudential Jennison Health Sciences A | 1416506 | 0.80% | -- | -- | 2018-07-31 |
| PowerShares QQQ ETF | 1447805 | 0.81% | -5580 | -0.38% | 2018-09-13 |
| VA CollegeAmerica New Economy 529F | 1535130 | 0.86% | -- | -- | 2018-06-30 |
| Invesco American Franchise A | 986142 | 0.56% | 83490 | 9.25% | 2017-12-31 |
| CREF Growth R1 | 965839 | 0.55% | -8605 | -0.88% | 2017-12-31 |
| Vanguard Mid Cap Growth Inv | 916202 | 0.53% | 530740 | 137.69% | 2016-09-30 |
| T. Rowe Price Growth Stock | 917359 | 0.53% | -3200 | -0.35% | 2016-09-30 |
| Prudential Jennison Mid Cap Growth A | 857583 | 0.50% | -26675 | -3.02% | 2016-12-31 |
| Touchstone Sands Capital Select Growth Z | 968681 | 0.60% | -53000 | -5.20% | 2016-09-30 |
| VA CollegeAmerica AMCAP | 6848011 | 4.20% | -77503 | -1.10% | 2015-09-30 |
| Fidelity® Select Biotechnology Portfolio | 5122477 | 3.20% | 69860 | 1.40% | 2015-09-30 |
| VA CollegeAmerica New Economy | 2172400 | 1.40% | 86000 | 4.10% | 2015-09-30 |
| T. Rowe Price Growth Stock Fund | 2025100 | 1.30% | -222800 | -9.90% | 2015-09-30 |
| Prudential Jennison Health Sciences | 1752708 | 1.10% | -- | -- | 2015-09-30 |
| Touchstone Sands Capital Select Growth | 1651000 | 1.00% | -19000 | -1.10% | 2015-08-31 |
| Fidelity Advisor® Biotechnology Fund | 1417848 | 0.90% | 17097 | 1.20% | 2015-09-30 |
| VA CollegeAmerica Growth Fund of America | 8060428 | 5.00% | 45000 | 0.60% | 2015-09-30 |
| JPMorgan Large Cap Growth | 1381900 | 0.90% | 7300 | 0.50% | 2015-09-30 |
| David E. I. Pyott | David E. I. Pyott is a British businessperson who has been at the head of 7 different companies. Currently, he holds the position of Chairman of Bioniz Therapeutics, Inc., Chief Executive Officer & Director at Serica Technologies, Inc. and President of Vicept Therapeutics, Inc. He is also President at International Council of Ophthalmology Foundation and on the board of 13 other companies. He previously occupied the position of Head-Nutrition Division at Novartis AG and President & Chief Executive Officer of Sandoz Nutrition Corp. (a subsidiary of Novartis AG), Chairman at California Healthcare Institute and Chairman & Chief Executive Officer of Allergan, Inc. Dr. Pyott received a graduate degree from The University of Edinburgh and an MBA from London Business School. |
|---|---|
| George Eric Davis | Currently, George Eric Davis holds the position of Secretary, Executive VP & General Counsel at BioMarin Pharmaceutical, Inc. and Secretary & Director at Biomarin (U.K.) Ltd. (a subsidiary of BioMarin Pharmaceutical, Inc.). In the past he occupied the position of Principal at Paul, Hastings, Janofsky & Walker LLP. Mr. Davis received an undergraduate degree from the University of California, Berkeley and a graduate degree from The University of San Francisco School of Law. |
| Wayne T. Pan | Wayne T. Pan is on the board of Semler Scientific, Inc. and Associate Medical Director at San Francisco Health Authority and Medical Director-Medical Sciences at BioMarin Pharmaceutical, Inc. He previously was Chief Medical Officer of Thrasys, Inc., Chief Medical Informatics Officer at Health Access Solutions, Inc., Chief Medical Officer at Affinity Medical Solutions LLC, Medical Director of Clover Health Labs LLC, Chief Medical Officer of Santa Clara County Individual Practice Association, Chief Medical Officer at Applied Research Works, Inc., Chief Medical Officer for Pacific Partners Management Services, Inc., Medical Director-Quality Care & Health Economics at Genentech, Inc. and Chief Medical Officer for Alameda Alliance for Health. Dr. Pan received an undergraduate degree from The Johns Hopkins University, a doctorate from Icah School of Medicine at Mount Sinai and an MBA from The Wharton School of the University of Pennsylvania. |
| Dennis Joseph Slamon | Dennis Joseph Slamon is on the board of BioMarin Pharmaceutical, Inc. and Translational Research In Oncology and Director-Clinical & Translational Research at Jonsson Comprehensive Cancer Center, Director-Revlon & UCLA Women Cancer Research at David Geffen School of Medicine and Executive Vice Chairman-Research at the University of California, Los Angeles. Dr. Slamon received an undergraduate degree from Washington & Jefferson College and a doctorate from Pritzker School of Medicine. |
| Jean-Jacques Bienaim�0�1�0�8 | Jean-Jacques Bienaim�0�1�0�8 holds the position of Chairman & Chief Executive Officer of BioMarin Pharmaceutical, Inc. He is also on the board of Incyte Corp., Biotechnology Innovation Organization and Pharmaceutical Research & Manufacturers of America. In the past he occupied the position of Lead Independent Director at NeurogesX, Inc., President & Chief Executive Officer at SangStat Medical Corp., Chairman, President & Chief Executive Officer at Genencor International, Inc., Director-Cardiopulmonary Products Marketing at Genentech, Inc. and Vice President & General Manager at Rhone-Poulenc Rorer Pharmaceuticals, Inc. Jean-Jacques Bienaim�0�1�0�8 received an undergraduate degree from ESCP Europe Campus Paris, an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree from The University of Texas. |
| Richard A. Meier | Richard A. Meier is on the board of BioMarin Pharmaceutical, Inc. In his past career he was CFO, Executive VP & President-International at Owens & Minor, Inc., Chief Financial Officer & Executive Vice President of Teleflex, Inc., President & Chief Operating Officer of Advanced Medical Optics, Inc., Chief Financial Officer & Executive Vice President of Valeant Pharmaceuticals International Corp., Senior Vice President of Schroder & Co., Inc., Principal at Manufacturers Hanover Corp., Principal at Greyhound Lines, Inc., Principal at Australian Capital Equity Pty Ltd. and Principal at Salomon Smith Barney, Inc. He received an undergraduate degree from Princeton University. |
| Richard J. Ranieri | Richard J. Ranieri holds the position of Senior VP-Human Resources & Corporate Affairs at BioMarin Pharmaceutical, Inc. Mr. Ranieri is also on the board of Xencor, Inc. In the past he occupied the position of Chief Administrative Officer & SVP-Human Resources at Neurocrine Biosciences, Inc., Executive VP-Human Resources & Administration at Sunovion Pharmaceuticals, Inc., Principal at GlaxoSmithKline LLC, Executive Vice President-Human Resources for Dendreon Corp. and Senior Vice President-Human Resources at Genencor International, Inc. Richard J. Ranieri received an undergraduate degree from Villanova University and a graduate degree from Rider University. |
| Daniel K. Spiegelman | Daniel K. Spiegelman founded Rapidscan Pharma Solutions, Inc. He is Chief Financial Officer & Executive Vice President for BioMarin Pharmaceutical, Inc. Mr. Spiegelman is also on the board of Rapidscan Pharma Solutions, Inc. and Tizona Therapeutics, Inc. In his past career he held the position of Chief Executive Officer for Filtini, Inc., Chairman of Relypsa, Inc., Chief Financial Officer & Senior Vice President at CV Therapeutics, Inc. and Treasurer at Genentech, Inc. He received an undergraduate degree from Stanford University and an MBA from Stanford Graduate School of Business. |
| Alan J. Lewis | Dr. Alan J. Lewis is an Independent Director at Assembly Biosciences, Inc., a President, Chief Executive Officer & Director at DiaVacs, Inc., a Chairman at Batu Biologics, Inc., a Chairman at Cellastra, Inc., an Independent Non-Executive Director at BioMarin Pharmaceutical, Inc., a Chairman at Cytochroma, Inc. and a Chairman at NeuraMetrix, Inc. He is on the Board of Directors at Scancell Holdings Plc, Assembly Biosciences, Inc., DiaVacs, Inc., Targazyme, Inc., BioMarin Pharmaceutical, Inc., BIOCOM, Capella Therapeutics, Inc., Habit DX, Inc., Rincon Pharmaceuticals, Inc., Scancell Ltd. and Sosei Co. Ltd. Dr. Lewis was previously employed as a Chief Executive Officer & Director by Medistem, Inc., a President, Chief Executive Officer & Director by Ambit Biosciences Corp., a President & Chief Executive Officer by Juvenile Diabetes Research Foundation Ltd., a President & Chief Executive Officer by Novocell, Inc. (Old), a President & Chief Executive Officer by Novocell, Inc. (New), a President by Celgene Research & Development Co. LLC, a President & Chief Executive Officer by Signal Pharmaceuticals, Inc., a Vice President-Research by Wyeth-Ayerst Research, a Research Associate by Yale University, a Non-Executive Director by Biotica Technology Ltd., a Chairman by LymphoSign, Inc., a Chairman by Novation Pharmaceuticals, Inc., a Chief Executive Officer by Signal Therapeutics, Inc., a Non-Executive Director by Sosei Group Corp., and a Principal by Wyeth Laboratories, Inc. He also served on the board at Discovery Partners International, Inc. He received his undergraduate degree from The University of Southampton and a doctorate degree from The University of Wales. |
| Henry J. Fuchs | Henry J. Fuchs holds the position of President-Worldwide Research & Development at BioMarin Pharmaceutical, Inc. He is also on the board of Genomic Health, Inc. and Mirati Therapeutics, Inc. In the past Dr. Fuchs occupied the position of Independent Director at Ardea Biosciences, Inc., Chief Medical Officer & Executive Vice President at Onyx Pharmaceuticals, Inc. and Principal at Genentech, Inc. Henry J. Fuchs received a doctorate from George Washington University and an undergraduate degree from Harvard University. |
| Robert A. Baffi | Robert A. Baffi is on the board of National Institute for Bioprocessing Research & Training and Executive Vice President-Technical Operations at BioMarin Pharmaceutical, Inc. In the past Dr. Baffi held the position of Research Scientist at Cooper Biomedical, Inc. Dr. Baffi received an undergraduate degree, a doctorate and a graduate degree from City University of New York and an MBA from Regis University. |
| Eduardo E. Von Pervieux | Eduardo E. Von Pervieux occupies the position of Chief Information Officer at BioMarin Pharmaceutical, Inc. In his past career he held the position of Director-Business Process & Technology at Pfizer Inc. and Executive Director-Systems & Business Process at Amgen, Inc. He received a graduate degree and an MBA from the University of Miami and an undergraduate degree from Florida International University. |
| Elaine J. Heron | Elaine J. Heron is on the board of BioMarin Pharmaceutical, Inc. and 4 other companies. In the past she was Chairmen & Chief Executive Officer at Labcyte, Inc., General Manager, Vice President-Sales & Marketing at Applera Corp., Vice President-Marketing at Affymetrix, Inc., Director-Marketing at Molecular Dynamics, Inc. and Vice President of Applied Biosystems, Inc. Dr. Heron received an MBA from Pepperdine University and a doctorate and an undergraduate degree from Purdue University. |
| V. Bryan Lawlis | Founder of Itero Biopharmaceuticals LLC, Covance Biotechnology Services, Inc. and Itero Biopharmaceuticals, Inc., V. Bryan Lawlis is on the board of Geron Corp. and 6 other companies. In his past career Dr. Lawlis occupied the position of Director at Aradigm Corp., President & Chief Executive Officer of Itero Biopharmaceuticals LLC, President & Chief Executive Officer at Itero Biopharmaceuticals, Inc., Chairman for Covance Biotechnology Services, Inc., Vice President-Process Sciences at Genentech, Inc. and Senior Scientist at Genencor International, Inc. V. Bryan Lawlis received an undergraduate degree from The University of Texas and a doctorate from Washington State University. |
| Geoffrey M. Nichol | Presently, Geoffrey M. Nichol is Chief Medical Officer & Senior Vice President of BioMarin Pharmaceutical, Inc. He previously held the position of Executive Vice President-Research & Development at Sangamo Therapeutics, Inc., Clinical Research Physician at GlaxoSmithKline Plc, Chief Medical Officer at Ikaria, Inc., Head-Global Project Management at Novartis Pharmaceuticals Corp. and Senior Vice President-Product Development at Medarex, Inc. He received an MBA from the University of Warwick and a doctorate and an undergraduate degree from Dunedin School of Medicine. |
| Michael G. Grey | Founder of Mirum Pharmaceuticals, Inc., Lumena Pharmaceuticals, Inc. and Reneo Pharmaceuticals, Inc., Michael G. Grey is an entrepreneur and businessperson who has been the head of 14 different companies and currently is Executive Chairman of Amplyx Pharmaceuticals, Inc., Executive Chairman for Reneo Pharmaceuticals, Inc., Executive Chairman of Spruce Biosciences, Inc., Executive Chairman for Mirum Pharmaceuticals, Inc. and Venture partner at Pappas Capital LLC. Michael G. Grey is also on the board of 7 other companies. In the past Mr. Grey held the position of President & Chief Operating Officer for Ansan, Inc., Independent Director at Ziarco Pharma Ltd., Executive Chairman for Ziarco Group Ltd., Non-Executive Chairman for IDM Pharma, Inc., President, Chief Executive Officer & Director at Lumena Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Trega Biosciences, Inc., President & Chief Executive Officer at SGX Pharmaceuticals, Inc., President & Chief Operating Officer of Ansan Pharmaceuticals, Inc., President of Biochem Therapeutic, Inc., President & Chief Executive Officer for Auspex Pharmaceuticals, Inc., Vice President-Corporate Development of Glaxo, Inc. and Vice President-Corporate Development of Glaxo Holdings Plc. He received an undergraduate degree from The University of Nottingham. |
| Jean-Jacques Bienaim�0�1�0�8 | Jean-Jacques Bienaim�0�1�0�8 holds the position of Chairman & Chief Executive Officer of BioMarin Pharmaceutical, Inc. He is also on the board of Incyte Corp., Biotechnology Innovation Organization and Pharmaceutical Research & Manufacturers of America. In the past he occupied the position of Lead Independent Director at NeurogesX, Inc., President & Chief Executive Officer at SangStat Medical Corp., Chairman, President & Chief Executive Officer at Genencor International, Inc., Director-Cardiopulmonary Products Marketing at Genentech, Inc. and Vice President & General Manager at Rhone-Poulenc Rorer Pharmaceuticals, Inc. Jean-Jacques Bienaim�0�1�0�8 received an undergraduate degree from ESCP Europe Campus Paris, an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree from The University of Texas. |
| Brian R. Mueller | Presently, Brian R. Mueller occupies the position of Chief Accounting Officer, SVP-Finance & Controller at BioMarin Pharmaceutical, Inc. He is also on the board of Anthera Pharmaceuticals, Inc. and Member of The American Institute of Certified Public Accountants and Vice President at Professional Control Corp. Brian R. Mueller previously was Principal at Arthur Andersen LLP and Senior Manager at KPMG LLP. He received an undergraduate degree from Northern Illinois University. |
| S. Michael Imperiale | S. Michael Imperiale is on the board of ScripsAmerica, Inc. and Senior Director-Global Medical Affairs at BioMarin Pharmaceutical, Inc. He previously occupied the position of Director-Clinical Trials Development at Exelixis, Inc., Director-Clinical Science at InterMune, Inc., Vice President-Clinical Research Operations at Talon Therapeutics, Inc., Senior Director-Medical Sciences at Nuvelo, Inc. and Senior Associate Director-Clinical Scientific at Boehringer Ingelheim Pharmaceuticals, Inc. He received a doctorate from Hahnemann University and an undergraduate degree from Villanova University. |
| Robert J. Hombach | Robert J. Hombach is on the board of BioMarin Pharmaceutical, Inc., CarMax, Inc., Aptinyx, Inc. and EDGe Surgical, Inc. In his past career he was Chief Financial Officer & Vice President at Baxter International, Inc., Executive VP, Chief Operations & Financial Officer at Baxalta, Inc. and President & Director at Baxter International Foundation. Mr. Hombach received an undergraduate degree from The University of Colorado and an MBA from Kellogg School of Management. |
| Stuart Bunting | Stuart Bunting is Head-Translational Biology at BioMarin Pharmaceutical, Inc. |
| Jeffrey Robert Ajer | Jeffrey Robert Ajer is on the board of Nektar Therapeutics and True North Therapeutics, Inc. and Chief Commercial Officer & Executive VP of BioMarin Pharmaceutical, Inc. In his past career Mr. Ajer held the position of Chief Commercial Officer & Executive VP of BioMarin Pharmaceutical, Inc., Vice President-Global Transplant Operations at Genzyme Corp., Director-Purchasing Worldwide at Valeant Pharmaceuticals International Corp. and Senior Director-Sales Operations, Bids & Contracts at SangStat Medical Corp. Mr. Ajer received an MBA and an undergraduate degree from the University of California, Irvine. |
| Eduardo E. Von Pervieux | Eduardo E. Von Pervieux occupies the position of Chief Information Officer at BioMarin Pharmaceutical, Inc. In his past career he held the position of Director-Business Process & Technology at Pfizer Inc. and Executive Director-Systems & Business Process at Amgen, Inc. He received a graduate degree and an MBA from the University of Miami and an undergraduate degree from Florida International University. |
| Philip Lo Scalzo | Philip Lo Scalzo is Chief Compliance Officer & Senior Vice President at BioMarin Pharmaceutical, Inc. In his past career he occupied the position of Associate Attorney at Sedgwick LLP and Assistant General Counsel at Sanofi-Aventis U.S. LLC. He received a graduate degree from Brooklyn Law School and an undergraduate degree from Boston College. |
| Traci McCarty | Presently, Traci McCarty is Investor Relations Contact at BioMarin Pharmaceutical, Inc. In her past career she was Senior Director-Investor Relations at Onyx Pharmaceuticals, Inc. |
| Dennis Joseph Slamon | Dennis Joseph Slamon is on the board of BioMarin Pharmaceutical, Inc. and Translational Research In Oncology and Director-Clinical & Translational Research at Jonsson Comprehensive Cancer Center, Director-Revlon & UCLA Women Cancer Research at David Geffen School of Medicine and Executive Vice Chairman-Research at the University of California, Los Angeles. Dr. Slamon received an undergraduate degree from Washington & Jefferson College and a doctorate from Pritzker School of Medicine. |
| Willard H. Dere | Willard H. Dere is on the board of BioMarin Pharmaceutical, Inc., Radius Health, Inc., Mersana Therapeutics, Inc. and Seres Therapeutics, Inc. and Professor & Executive Director-Personalized Health at The University of Utah Health Sciences Center. In the past Dr. Dere was International Chief Medical Officer at Amgen, Inc. and Vice President-Endocrine & Bone at Eli Lilly & Co. He received an undergraduate degree and a doctorate from the University of California, Davis. |
| Dennis Joseph Slamon | Dennis Joseph Slamon is on the board of BioMarin Pharmaceutical, Inc. and Translational Research In Oncology and Director-Clinical & Translational Research at Jonsson Comprehensive Cancer Center, Director-Revlon & UCLA Women Cancer Research at David Geffen School of Medicine and Executive Vice Chairman-Research at the University of California, Los Angeles. Dr. Slamon received an undergraduate degree from Washington & Jefferson College and a doctorate from Pritzker School of Medicine. |
| Elizabeth McKee Anderson | Ms. Elizabeth M. Anderson is an Independent Non-Executive Director at Huntsworth Plc, an Independent Director at Bavarian Nordic A/S and an Independent Director at Bavarian Nordic GmbH. She is on the Board of Directors at BioMarin Pharmaceutical, Inc., Insmed, Inc., Aro Biotherapeutics Co., Huntsworth Plc, Bavarian Nordic A/S, Bavarian Nordic GmbH, Revolution Medicines, Inc., Bryn Mawr Hospital Foundation, PureSight Advisory LLC, The Haverford School and The Wistar Institute. Ms. Anderson was previously employed as a Vice President-Infectious Disease & Vaccines by Janssen Pharmaceuticals, Inc. and a VP& General Manager-Wyeth Lederle Vaccines by Johnson & Johnson. She received her undergraduate degree from Rutgers State University of New Jersey and an MBA from Loyola University New Orleans. |
| Camilla V. Simpson | Camilla V. Simpson is on the board of Spruce Biosciences, Inc. and Senior VP & Head-Product Portfolio Development at BioMarin Pharmaceutical, Inc. Ms. Simpson received a graduate degree from Birkbeck University of London, an undergraduate degree from National University of Ireland and an undergraduate degree from Kingston University. |
| Dave Jacoby | Dave Jacoby is Executive Group Medical Director at BioMarin Pharmaceutical, Inc. |
| Steve Maricich | Steve Maricich is Medical Director-Clinical Sciences at BioMarin Pharmaceutical, Inc. |
| Brad Glasscock | Brad Glasscock is Group VP & Head-Global Regulatory Affairs at BioMarin Pharmaceutical, Inc. |
| Brinda Balakrishnan | Brinda Balakrishnan founded Vision Medicines, Inc. Dr. Balakrishnan is Vice President-Corporate & Business Development at BioMarin Pharmaceutical, Inc. In her past career Dr. Balakrishnan occupied the position of VP-Corporate Strategy & Product Development at Vision Medicines, Inc. She received an undergraduate degree and a doctorate from Massachusetts Institute of Technology and a doctorate from Harvard Medical School. |
| Benjamin Kim | Benjamin Kim is Senior Medical Director-Clinical Science at BioMarin Pharmaceutical, Inc. |
| SAba Sile | SAba Sile is Medical Director of BioMarin Pharmaceutical, Inc. |
| Amy Wireman | Presently, Amy Wireman is Group Vice President-Human Resources at BioMarin Pharmaceutical, Inc. She received an undergraduate degree from New York University. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论